Kalmanovich Eran, Audurier Yohan, Akodad Mariama, Mourad Marc, Battistella Pascal, Agullo Audrey, Gaudard Philippe, Colson Pascal, Rouviere Philippe, Albat Bernard, Ricci Jean-Etienne, Roubille François
a Department of Cardiology , Montpellier University Hospital , Montpellier , France.
b Pharmacy Department , University Hospital of Montpellier , Montpellier , France.
Expert Rev Cardiovasc Ther. 2018 Nov;16(11):775-794. doi: 10.1080/14779072.2018.1530112. Epub 2018 Oct 15.
Heart failure (HF) has become a global pandemic. Despite recent developments in both medical and device treatments, HF incidences continues to increase. The current definition of HF restricts itself to stages at which clinical symptoms are apparent. In advanced heart failure (AdHF), it is universally accepted that all patients are refractory to traditional therapies. As the number of HF patients increase, so does the need for additional treatments, with an increased proportion of patients requiring advanced therapies. Areas covered: This review discusses extensive evidence for the effect of medical treatment on HF, although the data on the effect on AdHF is scare. Authors review the relevant literature for treating AdHF patients. Furthermore, mechanical circulatory devices (MCD) have emerged as an alternative to heart transplantation and have been shown to enhance quality of life and reduce mortality therefore authors also review the current literature on the different MCD and technologies. Expert commentary: More patients will need advanced therapies, as the access to heart transplantation is limited by the number of available donors. AdHF patients should be identified timely since the window of opportunities for advanced therapy is narrow as their morbidity is progressive and survival is often short.
心力衰竭(HF)已成为全球性疾病。尽管近年来药物和器械治疗都有进展,但HF的发病率仍在持续上升。HF的当前定义局限于临床症状明显的阶段。在晚期心力衰竭(AdHF)中,普遍认为所有患者对传统疗法均无效。随着HF患者数量的增加,对额外治疗的需求也在增加,需要先进疗法的患者比例也在上升。涵盖领域:本综述讨论了药物治疗对HF疗效的大量证据,尽管关于其对AdHF疗效的数据较少。作者回顾了治疗AdHF患者的相关文献。此外,机械循环装置(MCD)已成为心脏移植的替代方案,并已证明可提高生活质量和降低死亡率,因此作者还回顾了关于不同MCD及技术的当前文献。专家评论:由于心脏移植受可用供体数量限制,更多患者将需要先进疗法。AdHF患者应及时识别,因为先进治疗的机会窗口很窄,其病情呈进行性发展且生存期通常较短。